CG Invites Co (083790.KQ) Osake Kurssi

CrystalGenomics, Inc. generates revenue through its Finished Pharmaceuticals Manufacturing segment, which produces and sells finished pharmaceuticals. The Pharmaceutical R&D Division provides clinical trial analysis and technical services while also selling new drugs. The company also operates in the real estate leasing business under the segment structure. The Others segment manufactures and sells hot fats and other household items. Revenue streams are derived from pharmaceutical manufacturing, R&D services, real estate leasing, and household product sales. The primary buyers for finished pharmaceuticals include healthcare providers and distributors. Clinical trial analysis and new drug sales target pharmaceutical companies and research institutions. Real estate leasing serves commercial tenants, while hot fats and household items are sold to retail consumers. The company's segments collectively serve diverse markets across healthcare, real estate, and consumer goods. CrystalGenomics, Inc. focuses on therapeutic discovery and development, with its R&D Division driving innovation in new drug sales. The Finished Pharmaceuticals Manufacturing segment ensures steady supply of established products. Real estate leasing and household item sales provide additional revenue streams. The company's business model integrates pharmaceutical production, research, and non-pharmaceutical ventures.